Results 11 to 20 of about 1,009 (151)

Acute Myeloid Leukemia With Plasmacytoid Differentiating Cutaneous Lesions: A Case of Double Identity or Active Transformation. [PDF]

EJHaem
ABSTRACT Introduction Acute myeloid leukemia (AML) with plasmacytoid dendritic cell differentiation (pDC‐AML) is a newly described subtype of leukemia with features resembling blastic plasmacytoid dendritic cell neoplasm (BPDCN). Case Presentation Herein, we present a case of pDC‐AML in which bone marrow findings were best classified as AML, whereas ...
Lee BJ, Griffin SP, Jeyakumar D, Gamayo A, Rezk SA, Naqvi K.   +5 more
europepmc   +2 more sources

Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm. [PDF]

Cancer
Abstract Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic neoplasm that expresses CD123, is often observed in the bone marrow (BM), as well as skin, blood, and viscera. Tagraxofusp, a first‐in‐class CD123‐targeted therapy, is the only drug approved to treat BPDCN.
Konopleva M, Pemmaraju N, Sweet KL, Stein AS, Rizzieri DA, Wang ES, Vasu S, Rosenblat T, Zuurman M, Gupta I, Lane AA.   +10 more
europepmc   +2 more sources

First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial. [PDF]

Br J Haematol
British Journal of Haematology, Volume 207, Issue 6, Page 2592-2596, December 2025.
Stein AS, Lane AA, Sweet KL, Vasu S, Tosolini A, Katsetos J, Konopleva M, Pemmaraju N.   +7 more
europepmc   +2 more sources

Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm

Haematologica, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that presents with characteristic dark purple skin papules, plaques, and tumors, but may also involve the bone marrow, blood, lymph nodes, and central nervous system ...
Marlise R. Luskin, Andrew A. Lane
doaj   +1 more source

Regimen of Azacitidine Combined with GemOx in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report

Xiehe Yixue Zazhi, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly malignant hematological tumor derived from the precursor cells of plasmacytoid dendritic cells.
CHEN Xiaojun, LIU Yanquan, HU Xiaomei, HUANG Surong, SHEN Jianzhen   +4 more
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm Mimicking Erythema Nodosum: A Case Report

Annals of Internal Medicine: Clinical Cases, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as blastic natural killer cell lymphoma, is a rare, difficult-to-diagnose, and aggressive hematologic malignancy.
Marino Hirata, Nozomu Yoshino, Maya Takazawa, Hisashi Oshiro, Shinichi Kako, Hitoshi Sugawara   +5 more
doaj   +1 more source

Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts. [PDF]

Am J Hematol
ABSTRACT Although all myeloid cells are considered to derive from hematopoietic stem cells, the cells in each myeloid lineage are heterogeneous populations, and their distribution and functions vary, depending on underlying physiologic and pathologic processes, age, sex, and genetic and epigenetic signatures.
Valent P, Wojta J, Kovanen PT, Hermine O, Fend F, Sotlar K, Greinix H, Geissler K, Hartmann K, Schwaab J, Herling M, Boccuni L, Kazianka L, John MV, Sperr WR, Zierfuss C, Tzankov A, Sillaber C, Minkov M, Hoermann G, Collin M, Horny HP, Haferlach T, Sibilia M, Haroche J, La Rosée P, Orfao A, Arock M.   +27 more
europepmc   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report

Journal of International Medical Research, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematodermic malignancy derived from plasmacytoid dendritic cell precursors. Despite advances in our understanding of tumor cell surface markers, the pathogenesis of BPDCN remains
Xinmei Dang, Di Zhou, Lingjun Meng, Lintao Bi   +3 more
doaj   +1 more source

Single-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm

Frontiers in Immunology, 2022
The immune system represents a major barrier to cancer progression, driving the evolution of immunoregulatory interactions between malignant cells and T-cells in the tumor environment.
Erica A. K. DePasquale, Erica A. K. DePasquale, Erica A. K. DePasquale, Erica A. K. DePasquale, Daniel Ssozi, Daniel Ssozi, Marina Ainciburu, Jonathan Good, Jonathan Good, Jenny Noel, Jenny Noel, Martin A. Villanueva, Martin A. Villanueva, Martin A. Villanueva, Martin A. Villanueva, Martin A. Villanueva, Martin A. Villanueva, Charles P. Couturier, Charles P. Couturier, Charles P. Couturier, Alex K. Shalek, Alex K. Shalek, Alex K. Shalek, Alex K. Shalek, Alex K. Shalek, Alex K. Shalek, Sary F. Aranki, Hari R. Mallidi, Gabriel K. Griffin, Gabriel K. Griffin, Gabriel K. Griffin, Andrew A. Lane, Andrew A. Lane, Andrew A. Lane, Andrew A. Lane, Peter van Galen, Peter van Galen, Peter van Galen, Peter van Galen   +38 more
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Hematology, Transfusion and Cell Therapy, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with an aggressive clinical course and poor prognosis. BPDCN is most often characterized by its presentation with cutaneous lesions which are often asymptomatic, can be solitary or multiple lesions, can be distributed widely, and may range from bruise-like lesions to ...
openaire   +3 more sources